Chronocort

DRUG6 trials

Sponsors

Neurocrine UK Limited, Immedica Pharma AB

Conditions

21-Hydroxylase DeficiencyAdrenal InsufficiencyAdrenogenital SyndromeCongenital Adrenal HyperplasiaPrimary Adrenal Insufficiency

Phase 1

Comparison of Two Forms of Hydrocortisone in Patients With Congenital Adrenal Hyperplasia

CompletedNCT00519818

Neurocrine UK Limited21-Hydroxylase Deficiency, Adrenogenital Syndrome, Congenital Adrenal Hyperplasia

Start: 2007-08-31End: 2009-05-31Updated: 2022-04-26

An Open Label Study in Healthy Volunteers to Compare Chronocort® to Hydrocortisone

CompletedNCT03019614

Neurocrine UK LimitedAdrenal Insufficiency, Congenital Adrenal Hyperplasia

Start: 2010-03-01End: 2010-04-01Updated: 2026-09-14

A Two-part, Study to Compare the Pharmacokinetics and Dose Proportionality of up to 6 Chronocort Formulations

CompletedNCT03051893

Neurocrine UK LimitedAdrenal Insufficiency, Congenital Adrenal Hyperplasia

Start: 2011-02-01End: 2012-04-01Updated: 2026-09-14

Phase 2

Chronocort Versus Plenadren Replacement Therapy in Adults With Adrenal Insufficiency

CompletedNCT05222152

Neurocrine UK LimitedPrimary Adrenal Insufficiency

Start: 2021-11-23End: 2023-10-18Updated: 2026-09-14

Phase 3

Comparison of Chronocort Versus Standard Hydrocortisone Replacement Therapy in Participants Aged 16 Years and Over With Congenital Adrenal Hyperplasia

CompletedNCT05063994

Neurocrine UK LimitedCongenital Adrenal Hyperplasia

Start: 2022-05-24End: 2024-02-02Updated: 2026-10-02

Long-term Safety Study of Chronocort in the Treatment of Participants With Congenital Adrenal Hyperplasia

CompletedNCT05299554

Immedica Pharma ABCongenital Adrenal Hyperplasia

Start: 2022-04-01End: 2026-01-15Updated: 2026-06-18

Related Papers

Effects of modified release hydrocortisone on restoration of early morning cortisol, quality of life, and fatigue in adrenal insufficiency (The CHAMPAIN study): a randomised, double-blind, double-dummy, cross-over study comparing Chronocort and Plenadren.

2026-01-02